Skip directly to page options Skip directly to A-Z link
Volume 26, Number 3—March 2020
Research

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola

Jennifer K. Legardy-Williams1Comments to Author , Rosalind J. Carter1, Susan T. Goldstein, Olamide D. Jarrett, Elena Szefer, Augustin E. Fombah, Sarah C. Tinker, Mohamed Samai2, and Barbara E. Mahon2
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.K. Legardy-Williams, R.J. Carter, S.T. Goldstein, O.D. Jarrett, S.C. Tinker, B.E. Mahon); University of Illinois at Chicago, Chicago, Illinois, USA (O.D. Jarrett); The Emmes Corporation (E. Szefer); University of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Sierra Leone (A.E. Fombah, M. Samai)

Main Article

Table 2

Pregnancy outcome by risk for vaccine viremia during pregnancy among 48 women with estimated date of conception <60 days from vaccination, Sierra Leone Trial to Introduce a Vaccine against Ebola*

Characteristic Live birth Pregnancy loss Total Barnard’s exact p value
Immediate vaccinated, no. 17 14 31 1
High viremia risk 5 (56) 4 (44) 9 NA
Low viremia risk
 12 (55)
 10 (45)
 22
 NA
Deferred crossover vaccinated, no. 12 5 17 0.75
High viremia risk 6 (75) 2 (25) 8 NA
Low viremia risk
 6 (67)
 3 (33)
 9
 NA
Total vaccinated, no. 29 19 48 0.69
High viremia risk 11 (65) 6 (35) 17 NA
Low viremia risk 18 (58) 13 (42) 31 NA

*Values are no. (%) except as indicated. NA, not applicable.
†High viremia risk is defined as estimated date of conception before vaccination or 0–14 days after vaccination. Low viremia risk is defined as estimated date of conception 15–60 days after vaccination.

Main Article

1These first authors contributed equally to this article.

2These authors were co–principal investigators.

Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external